Navigation Links
Collexis Launches Innovative Reviewer Finder to Enhance the $30 Billion Health Research Grant Industry

COLUMBIA, S.C., Nov. 24 /PRNewswire-FirstCall/ -- Collexis Holdings Inc. (OTC Bulletin Board: CLXS), a leading developer of semantic search and knowledge discovery software, announced today the formal launch of the Reviewer Finder product, an application which identifies the best reviewers based on their research profile. By using the proprietary Collexis Fingerprint technology, a submitted grant proposal or submitted scientific manuscript is analyzed and the resulting document Fingerprint is compared against more than 1.8 million expert Fingerprints -- simultaneously checking for conflicts of interest based on co-authorship and organizational affiliation.

The Collexis Reviewer Finder helps grant funding organizations in two very important ways: first it assists in reducing the time to identify the most qualified reviewers from hours to virtually minutes, secondly it enhances security by identifying reviewers with potential conflicts of interest by instantly analyzing over 30 million relationships between the research community and peer review community. The Reviewer Finder tool is the latest enhancement to the suite of Collexis grant management applications. These services provide funding organizations with sophisticated portfolio analysis tools to assist in identifying gaps and trends and track the success of their funding by an institution, department or researcher.

"We are very pleased to offer this new application to the scientific community as it will greatly enhance the efficiency in the publishing of scientific articles," says Christian Herzog, MD, managing director STM. "It helps funding organizations and peer reviewed journals to reduce the amount of time to identify the right reviewer but -- equally important -- to increase security that the chosen reviewer has no conflict of interest."

Customers like the National Institutes of Health (NIH), the world's largest funder of life-science research, and the Wellcome Trust, the largest independent medical research charity in the UK, utilize the Collexis solution to ensure the objectivity of their grant funding processes. The NHLBI as one of the largest NIH institutes has started to implement the Collexis Reviewer Finder to identify the best reviewers in a customized version.

About Collexis Holdings, Inc.

Collexis Holdings, Inc., a leading developer of semantic search and knowledge discovery software is headquartered in Columbia, South Carolina (USA) with major operations in Cincinnati, Ohio, Geldermalsen, the Netherlands and Cologne, Germany. Collexis now offers the world's first pre-populated scientific social network for life science researchers, Collexis' proprietary technology builds conceptual profiles of text, called "Fingerprints", from documents, Websites, emails and other digitized content and matches them with a comprehensive list of pre-defined "Fingerprinted" concepts to make research results more relevant and efficient. This matching of concepts eliminates the ambiguity and lack of priority associated with word searches. The results are often described as "finding needles in many haystacks." Through this novel approach, Collexis can build unique applications to search, index and aggregate information as well as prioritize, trend and predict data based on sources in multiple industries without the limitations of language or dialect. Collexis' current clients in the public, private and academic sectors include the Mayo Clinic; Johns Hopkins University; Dana-Farber Cancer Institute, the University of California, San Francisco; the University of South Carolina; Erasmus University Library; Bristol-Myers Squibb; Lockheed Martin; the World Health Organization; Wellcome Trust; the National Institutes of Health; and the U.S. Department of Defense. Shares of Collexis common stock are traded under the symbol CLXS on the OTC Bulletin Board (OTC BB). For more information, visit .

Disclaimer: National Institutes of Health (NIH) is not considered a supporter or partner of Collexis.

Reference to NIH in the above shall not be construed as a Government endorsement nor does it obligate NIH to a position on or about the Collexis Software.

Forward-Looking Statements

Some of the statements made in this press release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management's current expectations and include known and unknown risks, uncertainties and other factors, many of which the company is unable to predict or control, that may cause the company's actual results or performance to differ materially from any future results or performance expressed or implied by such forward-looking statements. These statements involve risks and uncertainties, including risks and uncertainties associated with the company. These risks and uncertainties are in addition to other factors detailed from time to time in the company's filings with the SEC, including the section entitled "Risk Factors" in its transition report on Form 10-KSB for the period ended June 30, 2008. The company cautions investors that any forward-looking statements made by the company are not necessarily indicative of future performance. The company is not responsible for updating the information contained in this press release beyond the published date, or for changes made to this document by wire services or Internet services.

SOURCE Collexis Holdings Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Mayo Clinic to Pilot Collexis Expert Profiling
2. Collexis Healthcare to Expand Capabilities for Asklepios Group Utilizing Microsoft Solutions
3. Us TOO Launches National SEA Blue Campaign for Prostate Cancer Awareness Month
4. UPMC Health Plan Launches New Personal Health Record
5. Launches Video Contest for Young Directors
6. Academy of General Dentistry Launches Campaign to Focus on Tooth Erosion
7. Keeping Kids Healthy and Fit: The New York Kids Club Launches a Revolutionary New Fitness Program
8. Patient Advocate Foundation Launches Program to Help Uninsured Virginians with Chronic, Debilitating and Life-Threatening Illness Access Quality Healthcare
9. Mannatech Launches Phase One of New Sales and Training Tools
10. Coalition for Pulmonary Fibrosis Launches Aggressive Ad Campaign Directed at United States Congress
11. Actavis Launches Carvedilol Tablets in the U.S.
Post Your Comments:
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery ... of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , ... for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey ...
(Date:6/25/2016)... Aliso Viejo, California (PRWEB) , ... June 25, 2016 , ... ... preset to fit their specific project," said Christina Austin - CEO of Pixel Film ... all fully customizable and all within Final Cut Pro X . Simply select ...
(Date:6/25/2016)... Long Beach, CA (PRWEB) , ... June 25, 2016 , ... ... from UCLA with Magna Cum Laude and his M.D from the David Geffen School ... San Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... On Friday, ... presented a Bronze Wellness at Work award to iHire in recognition of their exemplary ... part of the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... A recent ... that most people are unfamiliar with. The article goes on to state that individuals ... also many of these less common operations such as calf and cheek reduction. The ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Research and Markets has announced the addition of the ... to 2022" report to their offering. ... financial data derived from varied research sources to present unique ... on the market during the next five years, including a ... markets, regional and country level analysis. The report provides a ...
(Date:6/23/2016)... 2016 Research and Markets has announced ... report to their offering. ... a favourable commercial environment for MedImmune to enter. The US ... will serve to drive considerable growth for effective anti-influenza medications. ... cap sales considerably, but development is still in its infancy. ...
(Date:6/23/2016)... VIEW, Calif. , June 23, 2016 ... a.m. CST on Thursday, July 7, 2016 , , , ... ) , , , , EXPERT PANELISTS:  , ... Nitin Naik; Senior Industry Analyst, Christi Bird; Senior Industry Analyst, Divyaa ... The global pharmaceutical industry is witnessing an ...
Breaking Medicine Technology: